November 04, 2020 SITC 2020 – second chances for Merck & Co and Oncosec Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
February 14, 2020 Astra turns to bispecifics to solve the treme problem Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
October 09, 2019 SITC 2019 preview – Nextcure’s time to shine The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.